A retrospective study of focused ultrasound versus cryotherapy in treatment of cervical squamous intraepithelial lesions

Figures & data

Figure 1. The study flowchart.

Table 1. Treatment group’s baseline demographic, behavioral, and clinical characteristics.

	FUS therapy (n = 144)	Cryotherapy (n = 106)	χ^2	p
Age (years)-no.(%)
18–24	9 (6.3)	11 (10.4)	χ^2=3.75	0.29
25–34	83 (57.6)	49 (46.2)
35–44	40 (27.8)	34 (32.1)
≥45	12 (8.3)	12 (11.3)
HPV^a-no. (%)			χ^2=1.44	0.70
Negative	26 (19.3)	14 (13.7)
Low-risk type	2 (1.5)	1 (1.0)
High-risk type	100 (74.1)	81 (79.4)
High-risk and low-risk types	7 (5.2)	6 (5.9)
Area of the lesion^b-no. (%)			χ^2=1.91	0.38
≤1/3	123 (85.4)	94 (88.7)
1/3 ∼ 2/3	19 (13.2)	9 (8.5)
≥2/3	2 (1.4)	3 (2.8)
Biopsy results-no. (%)			χ^2=0.01	0.98
LSIL	117 (81.3)	86 (81.1)
HSIL	27 (18.8)	20 (18.9)

^aThere were 9 cases of FUS group and 4 cases of cryotherapy group without prior HPV testing.

^bArea of lesions: the lesion and ectocervix area were marked by colposcopy software, and the proportion was calculated.

Table 2. Comparison of the efficacy of FUS therapy and cryotherapy.

	FUS therapy	Cryotherapy	χ^2	p	RR (95%CI)
3–6 Months
Over all participants followed up	144	106
No evidence of disease	132 (91.7%)	84 (79.2%)	8.017	0.005	2.811 (1.354,6.128)
HPV-positive at base line participants followed up	109	88
Clearance of HPV	84 (77.1%)	57 (64.8%)	3.616	0.057	0.547 (0.293,1.022)
6–12 Months
No evidence of disease at 3–6month follow-up participants followed up	125	82
Recurrent disease	1 (0.8%)	4 (4.9%)	1.978	0.160	0.157 (0.017,1.433)

Table 3. Comparison of the efficacy of FUS therapy and cryotherapy at different grades of lesions.

	LSIL				HSIL
	FUS therapy	Cryotherapy	χ^2	p	FUS therapy	Cryotherapy	χ^2	p
3–6 Months
Over all participants followed up	117	86			27	20
No evidence of disease	108 (92.3%)	69 (80.2%)	6.472	0.011	24 (88.9%)	15 (75.0%)	0.740	0.390
HPV-positive at base line participants followed up	82	69			27	19
Clearance of HPV	60 (73.2%)	43 (62.3%)	2.035	0.154	24 (88.9%)	14 (73.7%)	1.568	0.210
6–12 Months
No evidence of disease at 3–6 month follow-up participants followed up	101	67			24	15
Recurrent disease	1 (1.0%)	4 (6.0%)	1.950	0.163	0	0

Table 4. Complications by treatment.

complications	FUS therapy	Cryotherapy	χ^2	p
Bleeding requiring further treatment	4	0
Pain requiring medication	0	1
Local cervical infections	1	0
Others	0	1
Total	5 (3.5%)	2 (1.9%)	0.132	0.717